Dosing was initiated in a Phase 1 single and multiple ascending dose study of SCY-247, the Company's second-generation triterpenoid antifungal in development for the treatment of severe invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback